Why the study?
Although low-dose IL-2 has established safety and biological efficacy in IHD, its effects on vascular inflammation in patients with acute coronary syndromes remain to be assessed.
Does low-dose interleukin 2 reduce vascular inflammation in patients presenting with acute coronary syndromes?
Does low-dose interleukin 2 reduce vascular inflammation in patients presenting with acute coronary syndromes?
The IVORY trial protocol outlines a phase II study to evaluate whether low-dose interleukin 2 can reduce vascular inflammation in patients with acute coronary syndromes.
Answers are grounded in this paper and cite their sources.
Low-dose IL-2 is safe and expands Tregs in IHD/ACS; extends preclinical Treg data and supports efficacy trials.
Introduction Inflammation plays a critical role in the pathogenesis of atherosclerosis, the leading cause of ischaemic heart disease (IHD). Studies in preclinical models have demonstrated that an increase in regulatory T cells (Tregs), which have a potent immune modulatory action, led to a regression of atherosclerosis. The Low-dose InterLeukin 2 (IL-2) in patients with stable ischaemic heart disease and Acute Coronary Syndromes (LILACS) study, established the safety of low-dose IL-2 and its biological efficacy in IHD. The IVORY trial is designed to assess the effects of low-dose IL-2 on vascular inflammation in patients with acute coronary syndromes (ACS). Methods and analysis In this study, we hypothesise that low-dose IL-2 will reduce vascular inflammation in patients presenting with ACS. This is a double-blind, randomised, placebo-controlled, phase II clinical trial. Patients will be recruited across two centres, a district general hospital and a tertiary cardiac centre in Cambridge, UK. Sixty patients with ACS (unstable angina, non-ST elevation myocardial infarction or ST elevation myocardial infarction) with high-sensitivity C reactive protein (hsCRP) levels >2 mg/L will be randomised to receive either 1.5×10 6 IU of low-dose IL-2 or placebo (1:1). Dosing will commence within 14 days of admission. Dosing will comprise of an induction and a maintenance phase. 2-Deoxy-2-[fluorine-18] fluoro-D-glucose ( 18 F-FDG) positron emission tomography/CT (PET/CT) scans will be performed before and after dosing. The primary endpoint is the change in mean maximum target to background ratios (TBR max ) in the index vessel between baseline and follow-up scans. Changes in circulating T-cell subsets will be measured as secondary endpoints of the study. The safety and tolerability of extended dosing with low-dose IL-2 in patients with ACS will be evaluated throughout the study. Ethics and dissemination The Health Research Authority and Health and Care Research Wales, UK (19/YH/0171), approved the study. Written informed consent is required to participate in the trial. The results will be reported through peer-reviewed journals and conference presentations. Trial registration number NCT04241601 .
No takes yet. Share an insight, caveat, or question.
Sriranjan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: